Form 4: Entrada Therapeutics Executive Natarajan Sethuraman Reports Stock Transactions

Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics, reports acquisition and disposal of company stock and stock options.

Summary

• On March 1, 2025, Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics, was granted 60,800 restricted stock units (RSUs) and acquired 90,800 stock options.
• The RSUs vest in four equal installments on March 1st of 2026, 2027, 2028 and 2029.
• 25% of the option shares shall vest and become exercisable on March 1, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2029.
• On March 3, 2025, Sethuraman sold 6,138 shares of common stock at a weighted average price of $11.6786 to cover tax withholding obligations related to the vesting of previously granted RSUs.
• Following these transactions, Sethuraman directly owns 199,659 shares of Entrada Therapeutics common stock and 90,800 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects standard executive compensation practices and a routine stock sale for tax purposes. No significant positive or negative implications are immediately apparent.

Positives

• Grant of RSUs and stock options to a key executive suggests continued investment in the company's leadership and future.

Negatives

• Sale of shares to cover tax obligations, while common, could be perceived negatively if investors interpret it as a lack of confidence, although the amount is relatively small compared to total holdings.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term price volatility.

Future Outlook

The vesting schedules for the RSUs and stock options incentivize the executive to remain with the company through March 1, 2029.

Industry Context

Stock grants and options are common forms of executive compensation in the biotech industry, aligning management interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages in biotech companies of similar size and stage typically include a mix of salary, stock options, and restricted stock units.
• Vesting schedules are generally structured to incentivize long-term performance and retention, often spanning three to five years.
• Comparing the size of the grant to similar roles at companies like CRISPR Therapeutics or Beam Therapeutics would provide further context.

Stakeholder Impact

• The vesting schedule of the RSUs and stock options incentivizes the executive to remain with the company, which is beneficial for shareholders.
• The sale of shares to cover tax obligations has a minimal impact on shareholders.

Key Dates